Related Experiment Video
Updated: Feb 3, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Outcomes in preterm small versus appropriate for gestation infants after Bifidobacterium breve M-16 V supplementation
Gayatri Athalye-Jape1,2, Novia Minaee3, Elizabeth Nathan3
1Neonatal Directorate, King Edward Memorial Hospital for Women, Perth, Australia.
Insights
Routine probiotic supplementation with Bifidobacterium breve M-16V showed similar rates of necrotizing enterocolitis, late-onset sepsis, and mortality in preterm small for gestational age (SGA) versus appropriate for gestational age (AGA) infants. However, SGA infants required more time to reach full feeds.
Area of Science:
- Neonatal Medicine
- Microbiome Research
- Pediatric Gastroenterology
Background:
- Preterm infants, particularly those small for gestational age (SGA), face increased risks of feeding intolerance and adverse outcomes.
- Routine probiotic supplementation (RPS) with Bifidobacterium breve M-16V is used in neonatal intensive care units.
- Previous studies indicated comparable fecal bifidobacteria responses to B. breve M-16V in preterm SGA and appropriate for gestational age (AGA) infants.
Purpose of the Study:
- To compare clinical outcomes, including necrotizing enterocolitis (NEC), sepsis, and mortality, between preterm SGA and AGA infants receiving RPS with B. breve M-16V.
- To assess the impact of RPS on time to full enteral feeds in these infant groups.
Main Methods:
- Retrospective cohort study analyzing data from June 2012 to August 2015.
- Inclusion of preterm infants (<34 weeks gestation), with a subgroup analysis for infants <29 weeks gestation.
- Comparison of outcomes between SGA and AGA infants using multivariable regression, focusing on NEC (≥Stage II), all-cause mortality, late-onset sepsis (LOS), and postnatal age at full feeds (PAFF).
Main Results:
- While the primary outcome (NEC ≥ Stage II/all-cause mortality) was higher in SGA versus AGA infants <29 weeks (21% vs. 12%), rates of NEC (≥Stage II), LOS, and all-cause mortality were comparable between SGA and AGA infants across both <34 weeks and <29 weeks gestation groups.
- Median postnatal age at full feeds (PAFF) was significantly longer for SGA infants compared to AGA infants in both <34 weeks (8 vs. 7 days) and <29 weeks (14 vs. 11 days) groups.
- A trend toward reduction in the primary outcome was observed in AGA infants <34 weeks (8% vs. 6%).
Conclusions:
- Routine probiotic supplementation with Bifidobacterium breve M-16V did not significantly alter rates of NEC, LOS, or all-cause mortality in preterm SGA versus AGA infants.
- Preterm SGA infants supplemented with B. breve M-16V experienced a significantly longer duration to achieve full enteral feeds compared to their AGA counterparts.
- These findings highlight the need for tailored feeding strategies for preterm SGA infants even with probiotic use.
Abstract:
Introduction: Fecal bifidobacteria response after Bifidobacterium breve M-16 V supplementation was comparable in preterm small (SGA) versus appropriate for gestational age (AGA) infants.Objectives: To compare clinical outcomes between preterm SGA versus AGA infants after routine probiotic supplementation (RPS) with Bifidobacterium breve M-16V (3 × 109 CFU/day).Design: Retrospective cohort study (June 2012-August 2015) comparing outcomes between preterm (<34 weeks, subgroup: <29 weeks) SGA versus AGA infants after RPS with B. breve M-16 V using multivariable regression analysis. Primary outcome: necrotizing enterocolitis (NEC)≥Stage II/all-cause mortality. Secondary outcomes: NEC ≥ Stage II, all-cause mortality, late onset sepsis (LOS), postnatal age at full feeds (PAFF).Results: Outcomes in inborn 1380/1481 (162 SGA versus 1218 AGA) admissions were analyzed. Primary outcome "NEC ≥ Stage II /all-cause mortality" was higher in SGA versus AGA infants <29 weeks (21 versus 12%; p = .040), and showed trend toward reduction (8 versus 6%; p = .057) in AGA <34 weeks. NEC ≥ Stage II, LOS, and all-cause mortality was comparable in SGA versus AGA infants <34 weeks (3 versus 2, 9 versus 8, 9% versus 6%) and <29 weeks (5 versus 4, 16 versus 9, 18% versus 19%), respectively. Median (IQR) PAFF was significantly higher in SGA versus AGA infants <34 weeks (8 (6-12) versus 7 (5-10) days), and <29 weeks (14 (12-17) versus 11 (8-16) days).Conclusions: NEC, LOS and all-cause mortality rates were similar in preterm SGA versus AGA infants after RPS with Bifidobacterium breve M-16 V, but PAFF was higher in SGA infants.
More Related Videos
Related Concept Videos
Cattell's 16 Personality Factors
In contrast, source traits are the...
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Diabetes Mellitus: Type 2 and Gestational
Predicting Reaction Outcomes
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Drug Dosing: Infants and Children

